Profile of veliparib and its potential in the treatment of solid tumors

Inhibition of poly(ADP-ribose) polymerase (PARP) is an attractive therapeutic strategy because of the importance of this pathway in restoring DNA damage. Small-molecule inhibitors of PARP appear most effective when used to treat tumors with underlying defects in DNA repair, or when combined with DNA-damaging agents. Veliparib is one of several recently developed oral inhibitors of PARP currently in clinical trials. This review summarizes the pharmacology, mechanisms of action, toxicity, and activity of veliparib seen in clinical trials to date. Also discussed are proposed mechanisms of resistance, potential biomarkers of activity, and issues regarding patient selection and combination therapies that may optimize use of this exciting new agent.

• Publication year

  2015

• Venue

  OncoTargets and Therapy

• Publication date

  2015-07-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/OTT.S69935PMID 26251615PMCID 4524591
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Organoid model advances pancreatic cancer research.

  2015cited by this paper
• BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• HP1β Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy

  2015cited by this paper
• Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study

  2015cited by this paper
• Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

  2015cited by this paper
• Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies

  2014cited by this paper
• Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

  2014cited by this paper
• A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study

  2014cited by this paper
• Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

  2014cited by this paper
• A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis

  2014cited by this paper
• A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report.

  2014cited by this paper
• Targeting the DNA repair pathway in Ewing sarcoma.

  2014influential reference
• Complex Disease–, Gene–, and Drug–Drug Interactions: Impacts of Renal Function, CYP2D6 Phenotype, and OCT2 Activity on Veliparib Pharmacokinetics

  2014cited by this paper
• New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair

  2014cited by this paper
• Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung Cancer

  2014cited by this paper
• Phase II trial of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma (HCC).

  2014cited by this paper
• Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer

  2014cited by this paper
• ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

  2014cited by this paper
• PARP inhibitors in ovarian cancer: current status and future promise.

  2014cited by this paper
• Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition

  2014cited by this paper
• Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

  2013cited by this paper
• BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer

  2013cited by this paper
• A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity

  2013cited by this paper
• Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

  2013cited by this paper
• BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

  2013cited by this paper
• Cisplatin resistance associated with PARP hyperactivation.

  2013cited by this paper
• Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL

  2013cited by this paper
• Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma

  2013cited by this paper
• In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.

  2013cited by this paper
• Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).

  2013cited by this paper
• PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.

  2012cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• PARP Inhibitors

  2012cited by this paper
• A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

  2012cited by this paper
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

  2011cited by this paper
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cited by this paper
• Disposition and Drug-Drug Interaction Potential of Veliparib (ABT-888), a Novel and Potent Inhibitor of Poly(ADP-ribose) Polymerase

  2011cited by this paper
• The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.

  2011cited by this paper
• The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

  2011cited by this paper
• Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors.

  2010cited by this paper
• Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

  2009cited by this paper
• Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity

  2009cited by this paper
• Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

  2009cited by this paper
• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

  2008cited by this paper
• A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia.

  2008cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.

  2008cited by this paper
• ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

  2007cited by this paper
• Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models

  2007cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

  2000cited by this paper

• Benzimidazole Derivatives in Breast Cancer: Target-Specific Therapeutic Breakthroughs.

  2025cites this paper
• Multicenter Stroke Preclinical Assessment Network Analysis of Cardiovascular Risk Factor Subgroups Treated With the Poly(ADP‐Ribose) Polymerase Inhibitor Veliparib

  2025cites this paper
• SMARCA1 regulates PARP1-dependent ABC transporters expression and mediates doxorubicin resistance in triple-negative breast cancer

  2025cites this paper
• Mechanistic insights into P-glycoprotein-driven transport of anti-cancer PARP inhibitors.

  2025cites this paper
• Unveiling the research directions for pyrrolidine-based small molecules as versatile antidiabetic and anticancer agents.

  2025cites this paper
• Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer.

  2025cites this paper
• Establishment of patient-derived organoids and a characterization based drug discovery platform for treatment of gastric cancer

  2024cites this paper
• DNA damage response in breast cancer and its significant role in guiding novel precise therapies

  2024cites this paper
• Benzimidazole-based small molecules as anticancer agents targeting telomeric G-quadruplex and inhibiting telomerase enzyme.

  2024cites this paper
• Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation‐Responsive Nanovesicles for Lung Cancer Chemoradiotherapy

  2024cites this paper
• Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition

  2023cites this paper
• Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges.

  2023cites this paper
• Novel Fluorescent Benzimidazole-Hydrazone-Loaded Micellar Carriers for Controlled Release: Impact on Cell Toxicity, Nuclear and Microtubule Alterations in Breast Cancer Cells

  2023cites this paper
• DNA repair pathways in breast cancer: from mechanisms to clinical applications

  2023cites this paper
• Clinical efficacy of PARP inhibitors in breast cancer

  2023influential citation
• An epithelial–mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma

  2023cites this paper
• Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine

  2022cites this paper
• Cellular and molecular basis of therapeutic approaches to breast cancer.

  2022cites this paper
• Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development

  2022cites this paper
• Glioblastoma: Current Status, Emerging Targets, and Recent Advances

  2022cites this paper
• A Novel Classification Model for Lower-Grade Glioma Patients Based on Pyroptosis-Related Genes

  2022cites this paper
• A Review of Current treatment for Triple-Negative Breast Cancer (TNBC)

  2022cites this paper
• Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.

  2022cites this paper
• Veliparib for the treatment of solid malignancies

  2022cites this paper
• Effect and Safety of Therapeutic Regimens for Patients With Germline BRCA Mutation-Associated Breast Cancer: A Network Meta-Analysis

  2021cites this paper
• BENZIMIDAZOLE AS A PROMISING ANTIVIRAL HETEROCYCLIC SCAFFOLD: A REVIEW

  2021cites this paper
• Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target

  2021cites this paper
• Co-Encapsulation of Methylene Blue and PARP-Inhibitor into Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Enhanced PDT of Cancer

  2021cites this paper
• In vitro, in vivo and in silico-driven identification of novel benzimidazole derivatives as anticancer and anti-inflammatory agents

  2021cites this paper
• Small‐molecule Effectors of DNA Repair Proteins: Applications for Development of Cancer Therapeutics and Research

  2021cites this paper
• Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers.

  2020cites this paper
• Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas

  2020cites this paper
• Chromatin-Bound PARP1 Correlates with Upregulation of Inflammatory Genes in Response to Long-Term Treatment with Veliparib

  2020cites this paper
• Super-resolution visualization of distinct stalled and broken replication fork structures

  2020cites this paper
• Differential immunomodulatory Effect of PARP Inhibition in BRCA1 deficient and competent tumor cells.

  2020cites this paper
• A therapeutic update on PARP inhibitors: implications in the treatment of glioma.

  2020cites this paper
• The Effects of Doxorubicin, Ethanol Extract and Flavonoid-rich Fraction of Euphorbia Splendida Mobayen on the PARP Level, and APC Gene Expression in HT-29 Human Colon Cancer Cell Line

  2020cites this paper
• PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes—Implications for UV-Induced DNA Repair and Photocarcinogenesis

  2019cites this paper
• PARP1 inhibition alleviates injury in ARH3-deficient mice and human cells.

  2019cites this paper
• Veliparib: a new therapeutic option in ovarian cancer?

  2019cites this paper
• Synthesis, modeling studies and evaluation of E-stilbene hydrazides as potent anticancer agents

  2019cites this paper
• Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells

  2018cites this paper
• PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

  2018cites this paper
• An efficient one-pot conversion of carboxylic acids into benzimidazoles via an HBTU-promoted methodology

  2018cites this paper
• Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias

  2018cites this paper
• Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

  2018influential citation
• Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.

  2018cites this paper
• Double‐barreled gun: Combination of PARP inhibitor with conventional chemotherapy

  2018cites this paper
• Simulation results source for the identification of biological active compounds: synthesis, antimicrobial evaluation and SARs of three in one heterocyclic motifs

  2018cites this paper
• Adaptive mechanisms of resistance to anti-neoplastic agents.

  2017cites this paper
• Conventional and microwave-assisted synthesis of new 1H-benzimidazole-thiazolidinedione derivatives: A potential anticancer scaffold.

  2017cites this paper
• International Journal of Current Research in

  2017cites this paper
• Cellular responses to replication stress: Implications in cancer biology and therapy.

  2017cites this paper
• Novel poly(ADP-ribose) polymerase inhibitor veliparib: biophysical studies on its binding to calf thymus DNA

  2017cites this paper
• Hypervalent iodine(III) catalyzed rapid and efficient access to benzimidazoles, benzothiazoles and quinoxalines: Biological evaluation of some new benzimidazole-imidazo[1,2-a]pyridine conjugates

  2017cites this paper
• Enzymes in the Base Excision Repair Pathway as Targets for Small Molecule Mediated Therapeutics

  2017cites this paper
• PARP Inhibitors in Breast Cancer: Latest Evidence

  2017cites this paper
• Electrical Pulse-Mediated Veliparib for Effective Treatment of Triple Negative Breast Cancer: An in vitro Model Study

  2017cites this paper
• Targeting the DNA Damage Response for Treatment of Pediatric Glioblastoma

  2017cites this paper
• Effects of Veliparib on Microglial Activation and Functional Outcomes after Traumatic Brain Injury in the Rat and Pig

  2017cites this paper
• Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation

  2017influential citation
• PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs

  2017influential citation
• Current status of poly(ADP-ribose) polymerase inhibitors and future directions

  2017cites this paper
• Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.

  2017cites this paper
• Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers

  2017cites this paper
• Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study

  2017cites this paper
• Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy.

  2017cites this paper
• Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer

  2016cites this paper
• Role of Biomarkers in the Development of PARP Inhibitors

  2016cites this paper
• Design, Synthesis, and Biological Evaluation of Novel PARP-1 Inhibitors Based on a 1H-Thieno[3,4-d] Imidazole-4-Carboxamide Scaffold

  2016cites this paper
• Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study

  2016cites this paper
• Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.

  2016cites this paper
• Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR–p53–NF-κB interactions

  2016cites this paper
• Tumor Suppressor Gene ARID1A in Cancer: Recent Advances and Future Perspective

  2016cites this paper
• Electroporation-based Enhanced Anti- Cancer Effect of Veliparib on Triple Negative Breast Cancer Cells

  2016cites this paper
• ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis

  2016cites this paper
• Veliparib for the treatment of ovarian cancer

  2016influential citation
• A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale

  2016cites this paper
• BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing

  2016cites this paper
• New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors

  2016cites this paper
• Microglial activation induced by the alarmin S100B is regulated by poly(ADP‐ribose) polymerase‐1

  2016cites this paper
• Exploration of Targeted Anti-tumor Therapy

  year unknowncites this paper